Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
firmonertinib + anlotinib + chemotherapy
- Development stage
- Unknown
- Lead developer
- Advenchen Laboratories
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Firmonertinib + anlotinib + chemotherapy is an investigational combination regimen being evaluated as neoadjuvant therapy for resectable, EGFR-mutant non-small cell lung cancer (NSCLC). The regimen consists of firmonertinib (brand name Ivesa; formerly furmonertinib), an oral, third-generation, small-molecule EGFR tyrosine kinase inhibitor (TKI); anlotinib, a small-molecule, multi-target TKI that inhibits VEGFR, PDGFR, FGFR, and c-Kit; and platinum-based doublet chemotherapy (such as carboplatin or cisplatin combined with pemetrexed). This combination is being studied in a prospective, multicenter, single-arm, Phase II exploratory clinical trial sponsored by Hubei Cancer Hospital to assess its efficacy and safety in patients with resectable EGFR-mutant NSCLC in the neoadjuvant setting.
- Other names
- firmonertinib combined with anlotinib and chemotherapyfirmonertinib combined with anlotinib and platinum-based doublet chemotherapyfurmonertinib + anlotinib + chemotherapyfurmonertinib combined with anlotinib and chemotherapyfurmonertinib combined with anlotinib and platinum-based doublet chemotherapy
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)DDR1 (Discoidin domain receptor 1)EGFR (Epidermal growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)MET (Mesenchymal-epithelial transition factor receptor)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)DNADHFR (Dihydrofolate reductase)GART (GAR transformylase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on firmonertinib + anlotinib + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on firmonertinib + anlotinib + chemotherapy.